BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34312798)

  • 1. Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load.
    Li B; Liu Z; Liu X; Liu D; Duan M; Gu Y; Liu Q; Ma Q; Wei Y; Wang Y
    Hepatol Int; 2021 Oct; 15(5):1103-1108. PubMed ID: 34312798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: Maternal ALT trajectory and infant outcomes.
    Chen HL; Lee CN; Chang CH; Lai MW; Tsai MC; Mu SC; Liu CJ; Shih JC; Wen WH; Hu RT; Huang CP; Hu KC; Chen CP; Lee CL; Chien RN; Chang KC; Hsu HY; Lee CC; Ni YH; Chang MH
    Liver Int; 2024 Jun; 44(6):1422-1434. PubMed ID: 38456620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the Efficacy and Safety of Tenofovir Disoproxil Fumarate in Intercepting Mother-to-Child Transmission of Hepatitis B Virus.
    Han D; Du J; Wang W; Wang C
    Acta Med Okayama; 2024 Apr; 78(2):107-113. PubMed ID: 38688828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic effectiveness analysis of tenofovir alafenamide and tenofovir disoproxil fumarate on the treatment for chronic hepatitis B.
    Liu R; Qiao J; Zhang L; Dou Z
    Medicine (Baltimore); 2024 May; 103(20):e37953. PubMed ID: 38758884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and Safety of Tenofovir Alafenamide Fumarate in the Prevention of Perinatal Hepatitis B Transmission: A Meta-Analysis.
    Huang J; Cheng C; Li K; Zhu C; Liu Y
    Dig Dis Sci; 2024 Mar; 69(3):978-988. PubMed ID: 38341392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy and safety of TAF, TDF, and LdT to prevent the transmission of hepatitis B in pregnant women: A retrospective study.
    Pan S; Zhang Y; Zeng Y; Lin C
    Immun Inflamm Dis; 2024 Feb; 12(2):e1204. PubMed ID: 38414328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
    Liu Z; Zhao Z; Ma X; Liu S; Xin Y
    BMC Gastroenterol; 2023 Nov; 23(1):384. PubMed ID: 37950196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide Fumarate (TAF) in Hepatitis B/HIV Co-Infection: A Feasibility Study.
    Lok J; Veloz MFG; Byrne R; Carey I; Childs K; Agarwal K; Nelson M
    Clin Ther; 2024 Feb; 46(2):159-163. PubMed ID: 38143153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of tenofovir in preventing perinatal transmission of HBV infection in pregnant women with high viral loads.
    Lin Y; Liu Y; Ding G; Touqui L; Wang W; Xu N; Liu K; Zhang L; Chen D; Wu Y; Bai G
    Sci Rep; 2018 Oct; 8(1):15514. PubMed ID: 30341345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of tenofovir alafenamide and entecavir for hepatitis B virus
    Peng W; Gu H; Jiang C; Liu J; Zhang J; Fu L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Feb; 47(2):194-201. PubMed ID: 35545409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of mother-to-child transmission of hepatitis B virus: protocol for a one-arm, open-label intervention study to estimate the optimal timing of tenofovir in pregnancy.
    Bierhoff M; Nelson KE; Guo N; Jia Y; Angkurawaranon C; Jittamala P; Carrara V; Watthanaworawit W; Ling C; Tongprasert F; van Vugt M; Rijken M; Nosten F; McGready R; Ehrhardt S; Thio CL
    BMJ Open; 2020 Sep; 10(9):e038123. PubMed ID: 32928858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tenofovir in preventing mother-to-infant transmission of hepatitis B virus: a meta-analysis based on 6 studies from China and 3 studies from other countries.
    Li W; Jia L; Zhao X; Wu X; Tang H
    BMC Gastroenterol; 2018 Aug; 18(1):121. PubMed ID: 30071845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study.
    Abe K; Obara T; Kamio S; Kondo A; Imamura J; Goto T; Ito T; Sato H; Takahashi N
    AIDS Res Ther; 2021 Dec; 18(1):94. PubMed ID: 34876151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma and Breast Milk Pharmacokinetics of Tenofovir Disoproxil Fumarate in Nursing Mother with Chronic Hepatitis B-Infant Pairs.
    Erturk US; Mete B; Ozaras R; Saltoglu N; Balkan II; Mert A; Kacmaz B; Saglam O; Guney B; Sayman OA; Tabak F
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0111021. PubMed ID: 34310204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
    Ogawa E; Nakamuta M; Koyanagi T; Ooho A; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Satoh T; Takahashi K; Azuma K; Yamashita N; Yamashita N; Sugimoto R; Amagase H; Kuniyoshi M; Ichiki Y; Morita C; Kato M; Shimoda S; Nomura H; Hayashi J;
    Aliment Pharmacol Ther; 2022 Aug; 56(4):713-722. PubMed ID: 35735794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir.
    Da Wang F; Zhou J; Li LQ; Li YJ; Wang ML; Tao YC; Zhang DM; Wang YH; Chen EQ
    Ann Hepatol; 2023; 28(5):101119. PubMed ID: 37271480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece.
    Sinakos E; Kachru N; Tsoulas C; Jeyakumar S; Smith NJ; Yehoshua A; Cholongitas E
    J Comp Eff Res; 2024 Apr; 13(4):e230090. PubMed ID: 38317634
    [No Abstract]   [Full Text] [Related]  

  • 18. Preventing viral relapse with prophylactic tenofovir in hepatitis B carriers receiving chemotherapy: a phase IV randomized study in Taiwan.
    Hsu CW; Chen SC; Wang PN; Wang HM; Chen YC; Yeh CT
    Hepatol Int; 2024 Apr; 18(2):449-460. PubMed ID: 38376651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-year Treatment with Tenofovir Alafenamide Achieves High Rates of Viral Suppression, Alanine Aminotransferase Normalization, and Favorable Bone and Renal Safety in Chinese Chronic Hepatitis B Patients.
    Hou J; Ning Q; Duan Z; Chen Y; Xie Q; Zhang L; Wu S; Tang H; Li J; Lin F; Yang Y; Gong G; Luo Y; Xie S; Wang H; Mateo R; Yazdi T; Abramov F; Yee LJ; Flaherty J; Chen C; Huang Y; Zhang M; Jia J
    J Clin Transl Hepatol; 2024 May; 12(5):469-480. PubMed ID: 38779514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Real-world study on the efficacy and safety of first-line antiviral therapy for chronic hepatitis B].
    Chang CD; Dong C; Zhao SX; Yuan XW; Zhang XX; Zhao DD; Dou Y; Nan YM
    Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):855-861. PubMed ID: 37723068
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.